Results 71 to 80 of about 69,891 (211)
Paromomycin: Uptake and resistance in Leishmania donovani [PDF]
Paromomycin is currently in phase IV clinical trials against leishmaniasis. In the present work we elucidate the effect and mechanism of uptake of paromomycin in Leishmania donovani. The in vitro sensitivities of both promastigotes and amastigotes were determined to this aminoglycoside. Association of paromomycin with L.
Anupam, Jhingran +4 more
openaire +2 more sources
Peptide‐enabled nanoplatforms offer multifunctional strategies for the treatment and diagnosis of malaria and leishmaniasis. Liposomal, polymeric, and metallic nanocarriers, together with cell‐penetrating peptides and parasite‐derived mimotopes, can improve targeted drug delivery, stability, bioavailability, and intracellular localization.
Christian S. Carnero Canales +7 more
wiley +1 more source
Molecular approaches for a better understanding of the epidemiology and population genetics of Leishmania. [PDF]
Molecular approaches are being used increasingly for epidemiological studies of visceral and cutaneous leishmaniases. Several molecular markers resolving genetic differences between Leishmania parasites at species and strain levels have been developed to
Kuhls, K +5 more
core +1 more source
BackgroundSeveral new species of Leishmania have recently emerged in Europe, probably as the result of global changes and increased human migration from endemic areas.
Jovana Sadlova +4 more
doaj +1 more source
Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis.
BackgroundVisceral leishmaniasis (VL), a widely distributed systemic disease caused by infection with the Leishmania donovani complex (L. donovani and L. infantum), is almost always fatal if symptomatic and untreated.
Tapan Bhattacharyya +9 more
doaj +1 more source
This review outlines a pioneering strategy to inhibit Leishmania infantum trypanothione reductase by disrupting its dimer interface. From peptides to small‐molecule proteomimetics, multiple chemotypes achieved potent enzymatic inhibition and notable cellular antileishmanial activity, highlighting a new therapeutic paradigm.
María‐José Camarasa +3 more
wiley +1 more source
ABSTRACT Background and Aims This narrative review aims to provide a comprehensive overview of tuberculosis (TB) in Sudan, focusing on prevalence, drug resistance patterns, and associated challenges while identifying knowledge gaps in scientific research and data needed for effective management.
Mohammad Azhar Kamal +3 more
wiley +1 more source
Visceral leishmaniasis (VL) is an important vector-borne disease caused by Leishmania donovani in the Indian subcontinent. The actual incidence and role of asymptomatic infections in the region are not well known.
Boelaert, M +29 more
core +1 more source
In the present context of emergence of resistance aligned with the conventional anti-leishmanial drugs and occasional treatment failure compelled us to continue the search for replaceable therapeutic leads against Leishmania infection.
Debarati Mukherjee +9 more
doaj +1 more source
A novel pyridine–thiazole derivative, Compound 8, exhibited potent dual antitrypanosomatid activity. It demonstrated remarkable in vitro efficacy against Trypanosoma cruzi (IC50 = 1.0 µM) and L. amazonensis (IC50 = 3.9 µM). Molecular docking studies suggested interactions with heme and multiple molecular targets.
Anderson José Firmino Santos da Silva +10 more
wiley +1 more source

